Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New acid blocker may beat standard drug for Post-Banding ulcers in cirrhosis

NCT ID NCT07608536

Prevention Sponsor: King George's Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether vonoprazan, a newer acid-blocking drug, is better than rabeprazole at preventing ulcers and bleeding after endoscopic variceal band ligation (EVL) in people with cirrhosis. About 300 adults with esophageal varices will take one of the two drugs daily for two weeks. After treatment, doctors will use an endoscope to measure ulcer size and count. The goal is to see which drug more effectively reduces ulcer-related complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vonoprazan and Rabeprazole
What this could lead to
If vonoprazan works better, it could offer a more effective way to prevent bleeding ulcers after variceal band ligation in people with cirrhosis.
What could go wrong
This is a phase 3 trial, but it's still early to know if vonoprazan is truly better. The study only follows patients for 2 weeks, so long-term benefits or risks are not assessed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years and above * Diagnosis of portal hypertension and esophageal varix should be established by endoscopy. * Who are willing to participate in the study Exclusion Criteria: * Negative consent * Diagnosed with HCC * Already taking PPI/Vonoprazan for other indications * Using anticoagulants and antiplatelets

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver esophageal varices portal hypertension ulcer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endoscopic variceal band ligation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • King George Medical University

    Lucknow, Uttar Pradesh, 226003, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.